Chinese biotech firm Biocytogen raises $65m
Biocytogen, a Chinese contract research organization (CRO) that provides genetically engineered mice for drug testing, has raised RMB410 million ($65 million) in a Series C round of funding led by CMB International Capital, an investment arm of China Merchants Bank.
Existing investors SDIC Venture Capital, a VC arm under the State Development & Investment Corporation (SDIC), 3E Bioventures, Cowin Capital and Oriza Holdings also took part in the round. The company...
More on Greater China
Latest News
Deal focus: Elevation targets Lumena uplift
Elevation Equity Partners sees Korean consumer electronics brand Lumena as a diamond in the rough, with high margins, quality products, and scope for domestic and international expansion
Deal focus: Mekong unconfined to consumer thesis
Having long eschewed industrial business models, consumer-focused Mekong Capital has made an exception in the name of environmental impact with Vietnam agricultural supplier Entobel
Fund focus: East Ventures expands its LP rolodex
Indonesia’s East Ventures reached beyond Asian LPs for the first time with its latest growth fund. It coincides with several other milestones that signal a new level of institutionalisation
Market volatility thwarts CVC pursuit of Australia's Brambles
CVC Capital Partners has abandoned its proposed acquisition of Australia-based container supplier Brambles, citing market volatility.